Mergers & Acquisitions
🇺🇸 FDA Page 3FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.
Showing 25–36 of 64 articles
White House Taps Amazon, GoodRx to Expand TrumpRx Generic Drug Access
The White House has partnered with Amazon Pharmacy and GoodRx to significantly expand TrumpRx.gov, integrating discounts for hundreds of generic drugs to enhance patient access and affordability.
BMS-Hengrui $15B Deal: Strategic Implications for Pharma Executives
Bristol Myers Squibb's significant $15 billion partnership with Hengrui Pharma signals a strategic shift, leveraging China's R&D capabilities for early-stage assets. This deal offers valuable insights for pharmaceutical business development and investment teams.
Longeveron Stockholder Letter Outlines 2026 Strategy and Partnership Focus
Longeveron has issued a stockholder letter detailing a strategic repositioning initiated in early 2026, aiming to maximize shareholder value through a capital-efficient, asset-light operating model. The company is prioritizing strategic licensing and partnering opportunities to advance its pipeline.
Eli Lilly Acquires Engage Bio to Advance Non-Viral Genetic Medicines
Eli Lilly has acquired Engage Bio in a deal valued up to $202 million, significantly bolstering its capabilities in non-viral genetic medicines. The acquisition centers on Engage's proprietary Tethosome platform, designed to overcome key challenges in DNA delivery.
TrumpRx Expands Generic Drug Offerings: Implications for Pharma BD and Investors
TrumpRx has significantly broadened its generic medicine catalog, adding over 600 new drugs to its platform. This strategic move aims to increase access to affordable medications and presents new considerations for pharmaceutical business development and investment strategies.
Eli Lilly's Strategic Vaccine Acquisitions: A New Era in Infectious Disease
Eli Lilly has strategically acquired three vaccine developers for up to $4 billion, significantly expanding its infectious disease pipeline. This move diversifies Lilly's portfolio and positions it for future growth in the vaccine market.
Big Pharma's Shift to Smaller Deals Boosts Biotech Sector
Big Pharma is strategically shifting its M&A focus from mega-deals to more disciplined, mid-sized acquisitions. This trend is proving to be a significant boon for the biotech sector, offering new avenues for growth and investment.
Rallybio Taps Avenzo Therapeutics for Reverse Merger to Advance Oncology Pipeline
Rallybio has entered into a merger agreement with Avenzo Therapeutics, a move that will see the combined entity focus on advancing next-generation oncology therapies. This strategic maneuver follows Rallybio's previous deal with Candid Therapeutics, signaling a significant pivot in its corporate strategy.
Rallybio Pursues Reverse Merger with Avenzo Therapeutics to Advance Autoimmune Pipeline
Rallybio is attempting a reverse merger with Avenzo Therapeutics, a move that will see the combined entity focus on Avenzo's T-cell engager pipeline for autoimmune diseases. The transaction includes a substantial concurrent financing round.
Merck's ADC Success: Insights from Global Trial Results
This article delves into Merck's successful antibody-drug conjugates (ADCs) and their global trial results, highlighting key insights for investors and BD teams.
Niowave's $75M Radiopharmaceutical Plant: Industry Implications
Niowave has initiated construction on a $75 million radiopharmaceutical plant in Michigan, marking a significant investment in Actinium-225 production. This development has far-reaching implications for the pharmaceutical industry and investment strategies.
Fierce Pharma Asia: Key Insights on Recent Deals and Trends
This article provides a comprehensive overview of the latest developments in the pharmaceutical industry, focusing on Pfizer's $10B Innovent deal and Astellas' strategic roadmap.